# Medpace Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Medpace Holdings, Inc.). ## Overview Medpace Holdings is a contract research organization that runs outsourced clinical development programs for biotechnology, pharmaceutical, and medical device companies. It provides full-service Phase I-IV trial support, combining therapeutic expertise, regulatory input, and global trial operations to help sponsors move products through development faster and more efficiently. ## Products & services • Full-service Phase I-IV clinical development • Clinical trial design and execution • Therapeutic-area expertise and regulatory support • Patient recruitment and investigator site management • Business development, marketing, and trial planning support - **Full-service clinical development** (85%) — End-to-end outsourced clinical trial services spanning Phase I through Phase IV. - **Therapeutic expertise and study consulting** (10%) — Scientific, medical, and regulatory support embedded into trial planning and execution. - **Operational and site management services** (5%) — Patient enrollment, investigator recruitment, and global trial coordination services. - Full-service Phase I-IV clinical development - Clinical trial design and execution - Therapeutic-area expertise and regulatory support - Patient recruitment and investigator site management - Business development, marketing, and trial planning support ## Customers Medpace sells primarily to biotechnology, pharmaceutical, and medical device sponsors that outsource clinical development rather than run trials entirely in-house. Its core appeal is strongest for small and mid-sized biopharmaceutical companies that want a full-service CRO partner with therapeutic depth, global reach, and disciplined execution. The company also serves larger sponsors on selected programs, but customer concentration and sponsor retention remain important to the model. - **Small and mid-sized biopharmaceutical companies** (primary) — They buy full-service clinical development because they often lack the internal infrastructure to run global trials efficiently. - **Biotechnology companies** (primary) — They outsource trial design, site management, and execution to accelerate development and conserve internal capital. - **Pharmaceutical companies** (secondary) — They use Medpace for selected programs and therapeutic-area expertise when they need external trial capacity. - **Medical device companies** (secondary) — They buy regulated clinical research services for device studies and related development programs. - Biotechnology sponsors outsourcing Phase I-IV trials - Pharmaceutical companies needing global clinical execution - Medical device companies requiring regulated study support - Small and mid-sized biopharma customers seeking full-service CRO coverage - Existing customers that award repeat studies and multi-program work ## Geography Medpace operates globally, with approximately 6,200 employees across 46 countries as of year-end 2025 and about 6,000 employees across 44 countries at mid-2025. The business depends on international trial sites, local regulatory know-how, and access to diverse patient populations, so geographic breadth is a core part of its operating model rather than just a sales footprint. - Global trial operations across 46 countries support patient access and site coverage - U.S. headquarters anchors sponsor relationships and corporate functions - International footprint improves regulatory execution and local market knowledge - Foreign earnings are indefinitely reinvested, indicating meaningful overseas operations - Country-level revenue disclosure was not provided in the excerpts ## Strategy Medpace is focused on expanding share in the Phase I-IV CRO market by emphasizing full-service delivery, therapeutic specialization, and disciplined execution. Management also highlights organic growth, selective bolt-on acquisitions, and continued investment in facilities, equipment, and technology to support capacity and service quality. - **Grow share in outsourced clinical development** (medium-term) — The company wants to capture more sponsor demand for full-service CRO outsourcing across the development lifecycle. - **Deepen therapeutic specialization** (medium-term) — Therapeutic expertise is a key differentiator in winning complex studies and repeat business. - **Invest in operating capacity and technology** (short-term) — Facilities, equipment, and systems support trial execution quality and future growth. - Expand share in the Phase I-IV CRO market - Win more work in Oncology, Metabolic, Cardiology, CNS, and AVAI - Use a full-service model to differentiate on speed and quality - Pursue selective bolt-on acquisitions and investments - Invest in infrastructure, technology, and global operating capacity ## Risks Medpace is exposed to sponsor concentration, contract timing, and execution risk because revenue depends on winning and completing clinical trials under fixed-fee or change-order-based arrangements. It also faces industry-wide CRO risks such as patient enrollment challenges, pricing pressure, regulatory disruption, cybersecurity, and global operating complexity. - **Sponsor contract loss or non-renewal** [high] — Revenue depends on ongoing clinical programs, so cancellations or delays can quickly reduce utilization and backlog conversion. - **Fixed-fee pricing and change-order execution** [high] — If study costs exceed estimates or change orders are delayed, margins can fall because the company bears execution risk. - **Customer and therapeutic concentration** [medium] — A limited number of large sponsors or therapeutic classes can create outsized exposure to program cancellations or class-wide setbacks. - **Patient recruitment and investigator availability** [high] — Trials depend on enrolling patients and securing investigators, and delays can push out revenue recognition and increase costs. - **Cybersecurity and information system outages** [high] — Clinical operations rely on systems such as ClinTrak and sensitive sponsor data, so breaches or outages can disrupt delivery and damage reputation. - **International and geopolitical exposure** [medium] — A broad country footprint creates exposure to local regulation, political instability, FX movements, and cross-border operating complexity. - Loss, delay, or non-renewal of sponsor contracts can reduce revenue - Backlog may not convert to revenue at historical rates - Fixed-fee underpricing and cost overruns can compress margins - Customer and therapeutic concentration can amplify volatility - Global operations expose the company to regulatory, political, and cyber risks ## Accounting The most important accounting judgment is revenue recognition on long-duration clinical contracts, especially where fixed fees, change orders, and backlog conversion timing affect when revenue and margin are recorded. Investors should also watch quarterly volatility, uncertain tax positions, lease commitments, and foreign earnings assertions, since these can materially affect reported earnings, liabilities, and liquidity presentation. - **Revenue recognition on clinical contracts** — Affects quarterly revenue, gross margin, and backlog conversion - **Backlog and contract estimates** — Affects revenue outlook and margin comparability - **Uncertain tax positions** — Can create future tax expense, interest, and penalties - **Foreign earnings indefinitely reinvested** — Affects tax expense and potential repatriation costs - **Lease and purchase commitments** — Affects liquidity disclosure and future cash requirements - Revenue recognition depends on contract progress, fixed fees, and change orders - Backlog conversion timing can shift revenue between quarters - Uncertain tax positions require judgment and can create future tax expense - Lease liabilities and purchase commitments affect cash needs and leverage optics - Foreign earnings are asserted indefinitely reinvested, affecting tax accounting --- *Last updated: 2026-04-28T20:26:50.385256+00:00*